Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pevonedistat plus azacitidine vs azacitidine in higher-risk MDS, CMML, or low-blast AML
jRCT2080223792Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) comparing Azacitidine + pevonedistat with Azacitidine monotherapy (2 arms). Started Jan 2018; status: completed.
02
Drugs
pevonedistatazacitidine
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCT2080223792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223792.